Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

(2011) Bang-Ning Lee et al.   CANCER

Analysis of Immunoglobulin VH Gene Repertoire by an Anchored PCR-Elisaa

(2010) LAURA Z. RASSENTI et al.   Annals of the New York Academy of Sciences

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

CCL3 (MIP-1 ) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

(2010) M. Sivina et al.   BLOOD

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response

(2010) Asher Chanan-Khan et al.   CANCER

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

(2010) Christine I. Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

(2009) B. F. Eichhorst et al.   BLOOD

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

(2009) J. A. Burger et al.   BLOOD

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

(2009) R. Lapalombella et al.   BLOOD

How I treat CLL up front

(2009) J. G. Gribben   BLOOD

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

(2009) G. Aue et al.   HAEMATOLOGICA

Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2009) Wolfgang U. Knauf et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of elderly patients with chronic lymphocytic leukemia

(2009) Barbara Eichhorst et al.   LEUKEMIA & LYMPHOMA

High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation

(2008) J. A. Burger et al.   BLOOD

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?

(2008) María-Victoria Mateos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2008) Kenneth A. Foon et al.   JOURNAL OF CLINICAL ONCOLOGY